CMAB Biopharma completed a $38 million Series A funding for its biologic CRO/CMO operations in Suzhou BioBay Park. The company offers process development and manufacturing services for biologic products. The funding was led by C-Bridge Capital, a healthcare PE investor involved mainly with China life science companies, along with BioBAY, a healthcare park, and joined by I-Bridge Capital and Qianhai FoF fund. I-Bridge is the early stage investor of the C-Bridge Group. CMAB intends to serve China and global biotech clients.
Source: China Biotoday
